Abstract
Ovarian cancer (OC) has a high incidence after menopause and represents a second most common gynecological cancer, second only to cervical cancer. Initially, OC respond to conventional treatments, like paclitaxel (PTX), thus decreasing the tumor mass growth; however, many women develop chemoresistance linked to immune response, and the disease progress with relapse. Melatonin (N-acetyl-5-…